Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of alpha-mangostin derivative in preparation of drugs for resisting and treating BPH (benign prostatic hyperplasia)

A technology of prostatic hyperplasia and mangostin, which is applied in the field of medicine, can solve the problem that α-mangostin is difficult to absorb, and achieve the effect of reducing prostate gland enlargement, improving SOD vitality, and broad application prospects

Active Publication Date: 2019-09-27
上海如凌生物医药有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] But so far, there has been no application of α-mangostin in benign prostatic hyperplasia. The reason may be that α-mangostin is difficult to be absorbed by prostate tissue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alpha-mangostin derivative in preparation of drugs for resisting and treating BPH (benign prostatic hyperplasia)
  • Application of alpha-mangostin derivative in preparation of drugs for resisting and treating BPH (benign prostatic hyperplasia)
  • Application of alpha-mangostin derivative in preparation of drugs for resisting and treating BPH (benign prostatic hyperplasia)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Effect of administration of α-mangostin derivatives on prostatic index in rats with benign prostatic hyperplasia.

[0030] 1. Set up animal groups: SD rats (200-220g, 6 rats in each group), randomly divided into groups. The grouping is shown in Table 1.1.

[0031] Table 1.1 Animals and groups required in Example 1

[0032]

[0033] 2. Administration and dosage: dissolve the α-mangostin derivative with a purity of more than 99% in DMA:PEG400:EtOH=30:40:30 (V:V:V), and inject the animal through the tail vein. For: 1mg / kg, 0.5mg / kg; positive drug Qianliekang administration: 20mg / kg, as positive control; model group and normal control group were given the same amount of solvent in the same way. Administration was administered at 11:00 every day, and administration was continued for seven days after modeling.

[0034] 3. Operation process: After the animal was anesthetized, the skin of the lower abdomen was cut to expose the left and right testicles, and a kn...

Embodiment 2

[0036] Example 2 Effects of administration of α-mangostin derivatives on the prostate index and the content of MDA and SOD in the prostate tissue of rats with benign prostatic hyperplasia.

[0037] After the rats were anesthetized with chloral hydrate, the prostate tissue was taken out, and its mass was measured with an analytical balance to make a relevant prostate index. The tissue of the same mass and part was homogenized with a tissue homogenizer, according to the MDA and SOD reagents of Nanjing Biological Construction Co., Ltd. The contents of MDA and SOD in tissues were determined according to the instructions of the box.

[0038] like figure 2 As shown, in the determination of MDA content, there was a significant difference between the model group and the normal group (P image 3 Shown, in SOD content determination, model group has significant difference (P<0.05) compared with normal group, and positive drug group has significant difference with model group rats, and hi...

Embodiment 3

[0040] Example 3 Effect of administration of α-mangostin derivatives on staining observation of prostate gland cells in rats with benign prostatic hyperplasia.

[0041] After rats were anesthetized with chloral hydrate, 4% paraformaldehyde (0.1M phosphate buffer, pH = 7.4) was used to separate the prostate tissue, immersed in 4% paraformaldehyde, stored in the dark at 4°C for 24 hours, and then immersed in 30% paraformaldehyde Sucrose solution for 3 days, sliced ​​with a cryostat. After the frozen sections are dried, add absolute alcohol for 5-10 minutes, and 75% alcohol for 3 minutes

[0042] Drop into the staining solution, 95% alcohol twice, xylene twice for 5 minutes each time, and finally seal the slide with neutral gum, let it dry naturally, the cells show mottled blue-purple staining, and take pictures under the microscope.

[0043] like Figure 4 As shown, the shape of the gland tissue in the normal group was intact, the size of the gland was small, the glandular epi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an alpha-mangostin derivative alpha-mangostin derivative in preparation of drugs for resisting and treating BPH (benign prostatic hyperplasia) and anti-BPH drug composition. The effective ingredient of the anti-BPH BPH drug composition is the alpha-mangostin derivative. The alpha-mangostin derivative can be absorbed by prostate tissue, still has anti-inflammatory activity, can improve the SOD activity and reduce MDA content and relieves enlargement of a prostate gland, therefore, the alpha-mangostin derivative can be used for treating BPH and has broad application prospects in preparation of the drugs for treating the BPH.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the application of an α-mangostin derivative in the preparation of anti-therapeutic prostatic hyperplasia drugs Background technique [0002] Benign prostatic hyperplasia (BPH) is characterized by hyperplasia of prostatic stroma and epithelial cells, and is the most common multiple disease in elderly men. The main manifestation is dysuria, which is caused by the progressive hypertrophy of the prostate gland and the compression of the urethra, resulting in an increase in the tension of the smooth muscle around the prostate, resulting in bladder outlet obstruction (Bladder outlet obstruction, BOO) and lower urinary tract symptoms (Lower urinary tract symptoms, LUTS) , mainly manifested as storage period symptoms: increased nocturia, frequent urination, urgency, urinary incontinence, etc.; urination period symptoms: difficulty urinating, shortened range, waiting for urin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P13/08
CPCA61K31/352A61P13/08
Inventor 陈艳吴婷婷叶润泽占扎君单伟光龚婷婷
Owner 上海如凌生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com